Comparison of Disease Severity Classifications of Chronic Obstructive Pulmonary Disease: GOLD vs. STAR in Clinical Practice

被引:1
|
作者
Nishimura, Koichi [1 ,2 ]
Kusunose, Masaaki [3 ]
Shibayama, Ayumi [4 ]
Nakayasu, Kazuhito [5 ]
机构
[1] Natl Ctr Geriatr & Gerontol, 7-430 Morioka Cho, Obu 4748511, Japan
[2] Clin Nishimura, 4-3 Kohigashi, Kuri Cho, Ayabe 6230222, Japan
[3] Natl Ctr Geriatr & Gerontol, Dept Resp Med, 7-430 Morioka Cho, Obu 4748511, Japan
[4] Natl Ctr Geriatr & Gerontol, Dept Nursing, 7-430 Morioka Cho, Obu 4748511, Japan
[5] Kondo PP Inc, Data Res Sect, 17-25 Shimizudani Cho, Tennoujiku, Osaka 5430011, Japan
关键词
chronic obstructive pulmonary disease (COPD); disease severity; Global Initiative for Chronic Obstructive Lung Disease (GOLD); STaging of Airflow obstruction by Ratio (STAR); St. George's Respiratory Questionnaire (SGRQ); COPD Assessment Test (CAT); AIR-FLOW LIMITATION; COPD; MORTALITY; EXACERBATIONS; PREDICTORS; DYSPNEA; INDEX; RATIO; FEV1; FVC;
D O I
10.3390/diagnostics14060646
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: In chronic obstructive pulmonary disease (COPD), there are two known classifications for assessing what is called disease severity. One is the Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification, which is based on the post-bronchodilator value of FEV1 (% reference). The other is the STaging of Airflow obstruction by Ratio (STAR), with four grades of severity in subjects with an FEV1/FVC ratio <0.70: STAR 1 >= 0.60 to <0.70, STAR 2 >= 0.50 to <0.60, STAR 3 >= 0.40 to <0.50, and STAR 4 <0.40. Purpose: The aim of this study was to compare the staging of COPD using the GOLD and STAR classifications in clinical practice. Methods: We reanalyzed data from our outpatient cohort study, which included 141 participants with COPD from 2015 to 2023. We compared mortality and COPD-specific health status between the GOLD 1 to 4 groups and the STAR 1 to 4 groups. Results: By simple calculation, GOLD and STAR severity classes coincided in 75 participants (53.2%). The weighted Bangdiwala B value with linear weights was 0.775. The participants were observed for up to 95 months, with a median of 54 months. Death was confirmed in 29 participants (20.5%). In univariate Cox proportional hazards analyses, there was a significant difference in mortality between the GOLD 1 and GOLD 3 + 4 groups, with the GOLD 1 group used as the reference [hazard ratio 4.222 (95% CI 1.298-13.733), p = 0.017]. However, there was no statistically significant predictive relationship between STAR 1 and STAR 2, or between STAR 1 and STAR 3 + 4. St. George's Respiratory Questionnaire (SGRQ) Total and COPD Assessment Test (CAT) scores were significantly different between all GOLD groups, except for the CAT score between GOLD 1 and GOLD 2. The SGRQ Total and CAT scores were significantly different between STAR 1 and STAR 3 + 4, but not between STAR 1 and STAR 2. Conclusion: From the perspective of all-cause mortality and COPD-specific health status, the GOLD classification is more discriminative than STAR.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] The Comparison of Clinical Variables in Two Classifications: GOLD 2017 Combined Assessment and Spirometric Stage of Chronic Obstructive Pulmonary Disease
    Candemir, Ipek
    Ergun, Pinar
    Kaymaz, Dicle
    Tasdemir, Filiz
    Egesel, Nurcan
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2018, 81 (04) : 281 - 288
  • [2] Health status instrument vs. prognostic instrument for assessing chronic obstructive pulmonary disease in clinical practice
    Louis, R.
    Corhay, J. L.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2010, 64 (11) : 1466 - 1466
  • [3] Discordance in treatment of chronic obstructive pulmonary disease following GesEPOC Guideline vs. GOLD
    Figueira Goncalves, J. M.
    Golpe, R.
    Esteban, C.
    Acosta-Sorensen, M.
    Veiga, I
    Guzman-Peralta, I
    REVISTA CLINICA ESPANOLA, 2021, 221 (09): : 536 - 539
  • [4] Spirometric Classifications of Chronic Obstructive Pulmonary Disease Severity as Predictive Markers for Clinical Outcomes: The HUNT Study
    Bhatta, Laxmi
    Leivseth, Linda
    Mai, Xiao-Mei
    Henriksen, Anne Hildur
    Carslake, David
    Chen, Yue
    Martinez-Camblor, Pablo
    Langhammer, Arnulf
    Brumpton, Ben Michael
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (08) : 1033 - 1037
  • [5] GOLD classifications and mortality in chronic obstructive pulmonary disease: the HUNT Study, Norway
    Leivseth, Linda
    Brumpton, Ben Michael
    Nilsen, Tom Ivar Lund
    Mai, Xiao-Mei
    Johnsen, Roar
    Langhammer, Arnulf
    THORAX, 2013, 68 (10) : 914 - 920
  • [6] The role of electrocardiography in evaluation of severity of chronic obstructive pulmonary disease in daily clinical practice
    Akturk, Faruk
    Biyik, Ismail
    Kocas, Cuneyt
    Erturk, Mehmet
    Yalcin, Ahmet Arif
    Savas, Ayfer Utku
    Kuzer, Firuzan Pinar
    Uzun, Fatih
    Yildirim, Aydin
    Uslu, Nevzat
    Cuhadaroglu, Caglar
    TUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX, 2013, 61 (01): : 38 - 42
  • [7] Markers of disease severity in chronic obstructive pulmonary disease
    Franciosi, LG
    Page, CP
    Celli, BR
    Cazzola, M
    Walker, MJ
    Danhot, M
    Rabe, KF
    Della Pasqua, OE
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2006, 19 (03) : 189 - 199
  • [8] A STAR Is Born: A New Approach to Assessing Chronic Obstructive Pulmonary Disease Severity
    Calverley, Peter M. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 208 (06) : 647 - 648
  • [9] Clinical practice guidelines for chronic obstructive pulmonary disease: A review and comparison of current resources
    Pierson, DJ
    RESPIRATORY CARE, 2006, 51 (03) : 277 - 288
  • [10] Comparison of Nutritional Status by Severity of the Disease among Elderly with Chronic Obstructive Pulmonary Disease
    Yahya, Nor Farahain
    Omar, Noraida
    Yusof, Barakatun Nisak Mohd
    Daut, Ummi Nadira
    Adznam, Siti Nur Asyura
    ANNALS OF NUTRITION AND METABOLISM, 2019, 75 : 83 - 83